TdIF1: a putative oncogene in NSCLC tumor progression

Yujuan Zhang, Zhigang Wang, Yanqing Huang, Muying Ying, Yifan Wang, Juan Xiong, Qi Liu, Fan Cao, Rakesh Kumar Joshi, Yanling Liu, Yuming Zhong, Meng Zhang, Keng Yuan, Nanjin Zhou, James Koropatnick, Wei‐Ping MinSignal 2018 · DOI

TL;DR

This study identifies TdIF1 as a novel, overexpressed protein in non-small cell lung cancer (NSCLC) that drives tumor progression. Silencing TdIF1 significantly inhibits NSCLC cell growth and tumor formation in vivo, suggesting TdIF1 is a promising therapeutic target.

What Problem Does This Paper Address?

Lung cancer, particularly NSCLC, remains a leading cause of cancer-related deaths globally. Its aggressive nature, tendency for metastasis, and development of treatment resistance pose significant challenges. Current treatments often hit a "therapeutic ceiling," highlighting the urgent need for novel therapeutic targets and diagnostic biomarkers. While many genes are implicated in cancer, the functional roles of many proteins, including TdIF1, in cancer signaling pathways are poorly understood. This paper aims to elucidate the role of TdIF1 in NSCLC progression and explore its potential as a therapeutic target.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They utilized The Cancer Genome Atlas (TCGA) database to analyze RNA-Seq data from NSCLC tumors and adjacent normal tissues, identifying differential gene expression.
  • Cell Culture and Manipulation: Human NSCLC cell lines (A549, H1299, H1975) and a normal lung cell line (BEAS-2B) were used. TdIF1 expression was silenced using shRNA lentiviral vectors.
  • In Vitro Assays:
    • Quantitative PCR (qPCR): To measure mRNA levels of TdIF1 and other genes.
  • Western Blotting: To assess protein expression levels.
  • Cell Proliferation Assays: Using Celigo image cytometry to quantify live cell numbers over time.
  • Colony Formation/Soft Agar Assay: To evaluate anchorage-independent growth.
  • In Vivo Xenograft Model: TdIF1-knockdown and control NSCLC cells were implanted into nude mice to assess tumor growth and weight.
  • Immunohistochemistry (IHC): To visualize TdIF1 protein localization in tissue samples.
  • Microarray and Pathway Analysis: To identify signaling pathways affected by TdIF1 knockdown, using Ingenuity Pathway Analysis (IPA).
  • Statistical Analysis: Standard statistical tests (t-tests, ANOVA, chi-square, Kaplan-Meier) were used to determine significance.

Datasets

  • TCGA RNA-Seq Data: Used for initial identification of TdIF1 upregulation in NSCLC tumors compared to adjacent normal tissues (57 paired samples).
  • Tissue Microarray: Contained 82 paired NSCLC cancerous and normal lung tissues, used for IHC validation of TdIF1 expression.
  • Human Lung Cancer Cell Lines: A549, H1299, and H1975 (NSCLC) and BEAS-2B (normal bronchial epithelial).
  • Nude Mice: Used for xenograft tumor models.
  • Affymetrix Gene Expression Microarray: Used for transcriptome analysis of TdIF1 knockdown vs. control cells.

Key Insights and Ideas

  • TdIF1 as a Novel Oncogene in NSCLC: The study provides strong evidence that TdIF1 is not just present but actively contributes to NSCLC development and progression.
  • Link to Poor Prognosis: High TdIF1 expression in clinical NSCLC samples is directly correlated with worse patient survival, making it a potential prognostic biomarker.
  • Mechanism Involves HDAC-p53 Axis: TdIF1 appears to regulate tumor growth by influencing the critical HDAC1/2-p53 signaling pathway, which is central to cell cycle control and apoptosis.
  • Targeting TdIF1 for Therapy: The significant suppression of tumor growth upon TdIF1 knockdown in both in vitro and in vivo models strongly suggests TdIF1 as a viable therapeutic target.

Key Results

  • Upregulation in NSCLC: TdIF1 was significantly upregulated in NSCLC tumor tissues compared to adjacent normal tissues (Fig. 1a, Table 1).
  • Association with Poor Prognosis: Patients with high TdIF1 expression showed significantly lower survival rates (Fig. 1b, P = 0.037).
  • Increased Expression in Cell Lines: TdIF1 was highly expressed in three NSCLC cell lines (A549, H1299, H1975) compared to a normal lung cell line (BEAS-2B) (Fig. 1d, e).
  • Inhibition of Proliferation: shRNA-mediated knockdown of TdIF1 in A549 cells suppressed cell proliferation (Fig. 2b).
  • Reduced Colony Formation: TdIF1-silenced cells formed significantly fewer colonies in soft agar assays (Fig. 2c).
  • Suppressed Tumor Growth In Vivo: Xenograft tumors derived from TdIF1-knockdown cells were significantly smaller and weighed less than those from control cells (Fig. 3a, b, c).
  • HDAC1/2 and p53 Modulation: TdIF1 knockdown led to downregulation of HDAC1 and HDAC2, and upregulation of acetylated p53 (Ac-p53) (Fig. 4d, e).
  • Cell Cycle Gene Regulation: TdIF1 silencing resulted in the upregulation of CDKN1A/p21 and downregulation of CDK4, CDK6, cyclin D1, CDC20, and CDC25C (Fig. 4f).

Limitations and Future Work

  • Limited Understanding of TdIF1 Network: While the study identified the HDAC-p53 axis as a key player, the full spectrum of genes and pathways regulated by TdIF1 remains to be elucidated. The authors mention that TdIF1 may transcriptionally regulate over 300 genes, most of which are uninvestigated.
  • Preclinical Focus: The study is largely preclinical, focusing on cell lines and mouse models. Further validation in human clinical trials is necessary.
  • Specificity of HDAC Inhibitors: The paper notes that existing HDAC inhibitors can target TdIF1, but further research is needed to optimize these therapies for NSCLC and understand potential off-target effects.
  • Future Directions: The authors suggest that TdIF1 could be a novel biomarker or molecular target for NSCLC therapy. They also propose investigating TdIF1's role in other aggressive, metastatic cancers. Further research into the precise mechanisms by which TdIF1 interacts with the HDAC-p53 axis and other cell cycle regulators is warranted.

Summary updated

Abstract

TdT-interacting factor 1 (TdIF1) is a ubiquitously expressed DNA- and protein-binding protein that directly binds to terminal deoxynucleotidyl transferase (TdT) polymerase. Little is known about the functional role of TdIF1 in cancer cellular signaling, nor has it previously been identified as aberrant in any type of cancer. We report here for the first time that TdIF1 is abundantly expressed in clinical lung cancer patients and that high expression of TdIF1 is associated with poor patient prognosis. We further established that TdIF1 is highly expressed in human non-small cell lung cancer (NSCLC) cell lines compared to a normal lung cell line. shRNA-mediated gene silencing of TdIF1 resulted in the suppression of proliferation and anchorage-independent colony formation of the A549 adenocarcinoma cell line. Moreover, when these TdIF1-silenced cells were used to establish a mouse xenograft model of human NSCLC, tumor size was greatly reduced. These data suggest that TdIF1 is a potent regulator of lung tumor development. Several cell cycle-related and tumor growth signaling pathways, including the p53 and HDAC1/2 pathways, were identified as participating in the TdIF1 signaling network by in silico analysis. Microarray, transcriptome and protein-level analyses validated p53 and HDAC1/2 modulation upon TdIF1 downregulation in an NSCLC cellular model. Moreover, several other cell cycle regulators were affected at the transcript level by TdIF1 silencing, including an increase in CDKN1A/p21 transcripts. Taken together, these results indicate that TdIF1 is a <i>bona fide</i> tumor-promoting factor in NSCLC and a potential target for therapy.
BibTeX
@inproceedings{zhang2018tdif,
  author = {Yujuan Zhang and Zhigang Wang and Yanqing Huang and Muying Ying and Yifan Wang and Juan Xiong and Qi Liu and Fan Cao and Rakesh Kumar Joshi and Yanling Liu and Yuming Zhong and Meng Zhang and Keng Yuan and Nanjin Zhou and James Koropatnick and Wei‐Ping Min},
  title = {{TdIF1: a putative oncogene in NSCLC tumor progression}},
  booktitle = {Signal},
  year = {2018},
  doi = {10.1038/s41392-018-0030-9},
}
Figure